 With RapidFire™ Lead Discovery, BioTrove scientists collaborate with researchers to design mass spectrometry-based high-throughput screening assays. These assays enable the identification of lead compounds against drug targets that may have previously been thought to be too expensive or technically impossible to screen. Over the past few years in multiple campaigns, BioTrove scientists developed dozens of assays and leveraged mass spectrometry to screen over 5 million compounds.
BioTrove uses ultra high throughput mass spectrometry to screen intractable drug targets such as: triglycerides, lipids, fatty acids, prostaglandins, steroids, Co-enzyme A derivatives, and neurotransmitters. Results from these assays can identify lead compounds to consider for further development as drugs in a wide range of therapeutic areas.
In addition to assay development, BioTrove also provides high throughput screening of customer libraries. Utilizing RapidFire™ ultra high throughput mass spectrometry technology, a 200,000 well screen can be completed in as little as one month.
|
 |
|
